draws from several key sources:

• FDA Guidance Documents: The FDA has issued several guidance documents, including the “Applying Human Factors and Usability Engineering to Medical Devices” guidance, which outlines expectations for human factors studies to support device submissions.
• Code of Federal Regulations (CFR): Specifically, Title 21 CFR Part 820 outlines the Quality System Regulation (QSR) requirements for device manufacturers, including design controls that relate to human factors.
• International Council for Harmonisation (ICH): ICH guidelines, particularly E6 (Good Clinical Practice), emphasize the importance of safety and efficacy throughout the drug development process, which includes consideration of user interaction with combination products.

Documentation

The documentation process for human factors submissions in NDA and BLA applications typically includes the following elements:

• Human Factors File: Comprehensive documentation that includes the results of human factors studies, usability testing data, and risk assessments related to human factors.
• User Research and Analysis: Detailed descriptions of how user needs, limitations, and preferences were identified and addressed throughout the design process.
• Usability Testing Protocols: Documentation of the methodologies used for usability testing, including participant selection, study design, and statistical analysis plans.
• Summaries of Human Factors Studies: Clear and concise summaries of all conducted studies, including objectives, methodologies, findings, and conclusions regarding the usability of the combination product.

Review/Approval Flow

The review and approval process for human factors submissions typically follows a structured pathway:

1. Pre-Submission Activities: Conducting preliminary user research and generating a draft human factors file.
2. Pre-Submission Meeting: Engaging with the FDA through a pre-submission meeting to discuss plans for human factors studies and gather initial feedback.
3. Submission of NDA/BLA: Including the comprehensive human factors file as part of the submission, supplemented with other required documents like CMC (Chemistry, Manufacturing, and Controls), clinical data, and labeling.
4. FDA Review Process: The review team will assess the human factors file as part of the overall application, focusing on whether usability and user-centric design were appropriately integrated.
5. Post-Approval Commitments: Addressing any deficiencies identified during the review process and conducting post-market surveillance on usability.

Common Deficiencies

When preparing submissions that include human factors data, it’s essential to be aware of common deficiencies that may arise during FDA review:

• Lack of Comprehensive User Input: Failure to engage target users throughout the development process can weaken the justification for design decisions. It is critical to demonstrate how user feedback influenced the product design.
• Inadequate Usability Testing: Submissions often lack robust data from usability testing, including a representative sample and appropriate statistical analysis. Ensure that studies are adequately powered and reflect real-world usage scenarios.
• Poor Risk Management: Inadequate identification and mitigation of user-related risks. Risk analyses must be thorough and aligned with relevant standards such as ISO 14971.
• Insufficient Documentation: Comprehensive record-keeping is vital; shortages in documentation can easily lead the FDA to raise concerns about the rigor of your human factors processes.

RA-Specific Decision Points

When to File as Variation vs. New Application

Determining whether to file a variation or a new application for a combination product largely depends on the extent of the changes made in response to human factors findings. Key considerations include:

• Magnitude of Change: Significant design modifications that could alter the product’s indications or change user interactions may require a new submission.
• Impact on Safety and Efficacy: If user feedback reveals substantial usability issues that necessitate new designs—reflecting a change in how the product is used—this may call for a new application.
• Regulatory Consultation: Engaging with regulatory agencies early can clarify whether a change necessitates a new filing or can be handled as a variation.

Justifying Bridging Data

In some cases, it may be necessary to justify the use of bridging data to support human factors assessments. Key factors to consider include:

• Similarity of Products: Use bridging data to support human factors claims if the previous product is substantially similar in terms of usage and design.
• Historical Usage Data: Data from established products can support safety claims. Ensure that this data is relevant and scientifically sound.
• User Population Characteristics: Demonstrating that the user population aligns closely between the products can strengthen the rationale for using bridging data in lieu of new studies.

Conclusion

In conclusion, the integration of human factors engineering into the regulatory strategy for NDA/BLA submissions involving combination products is critical to ensuring that these products meet the needs of users while complying with regulatory standards. By understanding the legal framework, preparing thorough documentation, navigating the review process effectively, and addressing common deficiencies, regulatory affairs professionals can contribute to successful product development and compliance. Continuous engagement with regulatory agencies, proactive planning, and robust user-centered design methodologies will be pivotal in the ongoing evolution of combination products in the global market.

For additional guidance on FDA human factors engineering, refer to the official FDA guidance document as it outlines specific expectations for human factors and usability engineering in the context of device submissions.